Clinicopathologic Variable | Training Cohort | Validation Cohort | ||||||
---|---|---|---|---|---|---|---|---|
Total | TRIM62 expression | P-value | Total | TRIM62 expression | P-value | |||
low | High | low | High | |||||
Age(years) | ||||||||
 ≦42 | 61 | 40 | 21 | 0.388 | 44 | 26 | 18 | 0.973 |
  > 42 | 47 | 27 | 20 | 37 | 22 | 15 | ||
FIGO stage | ||||||||
 Ia2 | 9 | 2 | 7 | 0.063 | 11 | 2 | 9 | 0.007 a |
 Ib1 | 56 | 34 | 22 | 39 | 22 | 17 | ||
 Ib2 | 18 | 12 | 6 | 14 | 9 | 5 | ||
 IIa1 | 12 | 8 | 4 | 7 | 6 | 1 | ||
 IIa2 | 13 | 11 | 2 | 10 | 9 | 1 | ||
Tumor size(cm) | ||||||||
 ≦4 | 74 | 41 | 33 | 0.036 | 54 | 27 | 27 | 0.016 |
  > 4 | 34 | 26 | 8 | 27 | 21 | 6 | ||
Pathologic types | ||||||||
 Squamous cell carcinoma | 68 | 43 | 25 | 0.738 | 53 | 30 | 23 | 0.503 |
 Adenocarcinoma | 40 | 24 | 16 | 28 | 18 | 10 | ||
Differentiation grade | ||||||||
 Well | 9 | 4 | 5 | 0.081 | 7 | 3 | 4 | 0.046 a |
 Moderate | 48 | 26 | 22 | 36 | 17 | 19 | ||
 Poor | 51 | 37 | 14 | 38 | 28 | 10 | ||
Stromal invasion | ||||||||
  < 1/2 | 61 | 30 | 31 | 0.004 | 50 | 25 | 25 | 0.031 |
 ≧1/2 | 47 | 36 | 11 | 31 | 23 | 8 | ||
 Lymphovascular space invasion | ||||||||
 Yes | 14 | 12 | 2 | 0.050 | 11 | 8 | 3 | 0.511a |
 No | 94 | 55 | 39 | 70 | 40 | 30 | ||
Pelvic-lymph node metastasis | ||||||||
 Yes | 18 | 15 | 3 | 0.041 | 14 | 11 | 3 | 0.106 |
 No | 90 | 52 | 38 | 67 | 37 | 30 | ||
Vaginal involvement | ||||||||
 Yes | 4 | 4 | 0 | 0.295a | 3 | 3 | 0 | 0.267a |
 No | 104 | 63 | 41 | 78 | 45 | 33 | ||
Parametrial infiltration | ||||||||
 Yes | 3 | 3 | 0 | 0.287a | 2 | 2 | 0 | 0.511a |
 No | 105 | 64 | 41 | 79 | 46 | 33 | ||
Recurrence | ||||||||
 Yes | 24 | 22 | 2 | 0.001 | 20 | 18 | 2 | 0.001 |
 No | 84 | 45 | 39 | 61 | 30 | 31 | ||
Vital status at follow-up | ||||||||
 Alive | 86 | 47 | 39 | 0.002 | 61 | 30 | 31 | 0.001 |
 Dead | 22 | 20 | 2 | 20 | 18 | 2 |